Breaking News
Get 40% Off 0
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2? Unlock full list
Close

Jounce Therapeutics Inc (JNCE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Jounce Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Jounce Therapeutics historical data, for real-time data please try another search
1.880 0.000    0.00%
03/05 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 1.880 - 1.930
Jounce Therapeutics 1.880 0.000 0.00%

Jounce Therapeutics Inc Company Profile

 
Get an in-depth profile of Jounce Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

141

Equity Type

ORD

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. As of May 3, 2023, Jounce Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Contact Information

Address 780 Memorial Drive
Cambridge, 02139
United States
Phone 857 259 3840
Fax 888 459 2940
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

JNCE Comments

Write your thoughts about Jounce Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Nhat Doan
Nhat Doan Dec 28, 2022 5:34AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Test Can Not SHORT 👉 Never Buy 👉 DELETE
יולן בר
יולן בר Aug 23, 2021 9:47AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀💰
Otto Gonzalez
Otto Gonzalez Sep 01, 2020 7:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I was ready to dump this stock and was waiting for the 7.45 range so I can break even since May timeline...I never expected the good news today.. this will explode with big pharma investors...I was pleasantly surprised today with this news. this originally had a target price of 9.50 and it should be a good investment for 2021..so hold on for the ride! ..
Fred Seow
Fred Seow Sep 01, 2020 12:20PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Worth 0.8B
Fred Seow
Fred Seow Sep 01, 2020 10:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Gilead signs with Jnce and will pay $35m upfront in shares and later up to $685m royalties, great news for Jnce
Jose Rodriguez
Jose Rodriguez Aug 10, 2020 5:44AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hello ! somebody have any new regarding JNCE, will it go up soon?
Jeong Roh
Jeong Roh Jan 20, 2020 7:08AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
target: $15
coach Shez
coach Shez Jun 04, 2018 3:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Short this ?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email